Symptom relief with LACRISERT ®

LACRISERT® acts like a slow-release, preservative-free artificial tear1,2

  • Prolongs the tear film breakup time
  • Provides ocular surface protection
  • Provided greater reduction of moderate to severe dry eye syndrome symptoms and signs than artificial tears
  • Stabilizes and thickens the precorneal tear film

LACRISERT® reduced the key symptoms of dry eye

Reduction in symptoms based on a multicenter, prospective, open-label patient registry (N=520)3

LACRISERT® can be used as adjunctive therapy for greater symptom reduction

53%
of patients felt that LACRISERT® improved the effectiveness of their existing therapy3,
Included artificial tears, punctal plugs, and cyclosporine emulsion.

Most patients remain on LACRISERT®

76%
of patients who received LACRISERT® remained on therapy 1 year later in a retrospective case study (n=80)1

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.
  • Instructions for inserting and removing LACRISERT should be carefully followed.
  • If improperly placed, LACRISERT may result in corneal abrasion. Because LACRISERT may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery.
  • The following adverse reactions have been reported, but were in most instances mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch.

Please see full Prescribing Information for LACRISERT® (hydroxypropyl cellulose ophthalmic insert).

References: 1. Wander AH, Koffler BH. Extending the duration of tear film protection in dry eye syndrome: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. Ocul Surf. 2009;7(3):154-162. 2. LACRISERT [package insert]. Bridgewater, NJ: Bausch & Lomb. 3. Koffler BH, McDonald M, Nelinson DS; for LAC-07-01 Study Group. Improved signs, symptoms, and quality of life associated with dry eye syndrome: hydroxypropyl cellulose ophthalmic insert patient registry. Eye Contact Lens. 2010;36(3):170-176.

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.

Important Safety Information

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.